The Fly | TalkMarkets | Page 138
Real-Time Financial News
Contributor's Links: TheFly.com
The Fly is a leading digital publisher of real-time financial news. Our financial market experts understand that news impacting stock prices can originate from anywhere, at any time. The Fly team scours all sources of company news, from mainstream to cutting-edge, ...more

Articles

Latest Posts
2193 to 2208 of 4122 Posts
<<< 1 ... 136 137 138 139 140 ... 258 >>>
On The Fly: Top Stock Stories For Friday, June 29, 2018
Stocks opened in positive territory after taking their cue from European and Asian markets, which traded higher overnight. Here is a brief roundup of notable economic events, company news and the major movers of the week.
FTC Says Court Ruled AbbVie Used 'Sham Litigation' To Maintain Androgel Monopoly
The U.S. District Court for the Eastern District of Pennsylvania ruled that AbbVie used sham litigation to illegally maintain its monopoly over the testosterone replacement drug Androgel and ordered $448 million in monetary relief.
Mizuho Says Synthetic Biologics IBS Treatment May Be 'Interesting' For Valeant
Mizuho analyst Irina Koffler raised her price target for Valeant Pharmaceuticals.
Disney Says DOJ Clears Pending Acquisition Of 21st Century Fox
The Walt Disney Company announced that the Antitrust Division of the United States Department of Justice has cleared the pending acquisition by Disney of Twenty-First Century Fox, Inc.
Disney Selects Cisco As Innovation Partner For StudioLAB
Cisco announced that it has been selected by The Walt Disney Studios as a founding member and Innovation Partner of The Walt Disney Studios StudioLAB.
UBS Ups Micron, Lam Research Ratings As Trends Improve
UBS analyst Timothy Arcuri upgraded Micron to Neutral as he sees producers taking a more anticipatory approach to DRAM supply.
GE Healthcare To Become Standalone Company, To Focus On Aviation, Power, RE
GE (GE) announced the results of its strategic review. GE will focus on Aviation, Power and Renewable Energy, creating a simpler, stronger, leading high-tech Industrial company.
Benchmark Says Buy Micron As Memory Trends Appear Sustainable
Benchmark analyst Mike Burton started Micron Technology with a Buy rating, stating that he sees little evidence of a supply glut in the company's DRAM business heading into the second half of this year.
PayPal Upgraded To Overweight On Expected Share Gains At Atlantic Equities
Atlantic Equities analyst Kunaal Malde upgraded PayPal to Overweight from Neutral, as he believes the company's differentiated checkout experience should enable the company to continue taking share.
Intel CEO Brian Krzanich Resigns, Board Names Bob Swan As Interim CEO
Intel announced the resignation of Brian Krzanich as CEO and a member of the Board of Directors. The Board has named CFO Robert Swan Interim CEO, effective immediately.
Netflix Price Target Raised To $500 From $420 At Pivotal Research
Pivotal Research analyst Jeffrey Wlodarczak raised his price target for Netflix to $500 from $420 and keeps a Buy rating on the shares.
What To Watch For In Micron's Earnings Report
Micron is scheduled to report results of its fiscal third quarter after the market close on June 20, with a conference call scheduled for 4:30 pm ET.
Morgan Stanley Questions If Starbucks Doing Enough, Downgrades To Equal Weight
Morgan Stanley analyst John Glass downgraded Starbucks to Equal Weight from Overweight after the company announced a same-store sales shortfall and cut its FY18 guidance.
Sarepta Price Target Raised To $168 From $83 At Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for Sarepta Therapeutics to $168 from $83 after the company presented Phase I/II data on three Duchenne muscular dystrophy boys receiving its micro-dystrophin gene therapy.
Deutsche Sees 23% Total Return Potential In Verizon, Upgrades Shares To Buy
Deutsche Bank analyst Matthew Niknam upgraded Verizon Communications to Buy from Hold with an unchanged price target of $56.
Roche Acquires Foundation Medicine For $137 Per Share Or $2.4B
Roche and Foundation Medicine announced they have entered into a definitive merger agreement for Roche to acquire the outstanding shares of Foundation Medicine not already owned by Roche and its affiliates at a price of $137.00 per share in cash.
2193 to 2208 of 4122 Posts
<<< 1 ... 136 137 138 139 140 ... 258 >>>